Section 4: Clinical Pharmacy Services

4CPS-121

COST-MINIMISATION ANALYSIS OF MAINTENANCE THERAPY OF ANTINEUTROPHIL CYTOPLASM ANTIBODY-ASSOCIATED VASCULITIDES

4CPS-120

ERLOTINIB IN NON-SMALL-CELL LUNG CANCER WITHOUT EPIDERMAL GROWTH FACTOR RECEPTOR ACTIVATING MUTATIONS

4CPS-119

EXPERIENCE OF NAB-PACLITAXEL AND GEMCITABINE USE IN METASTATIC PANCREATIC CANCER

4CPS-118

EXPERIENCE OF DUAL TARGETING USE OF NEOADJUVANT HER2-POSITIVE BREAST CANCER

4CPS-117

DOSE BANDING - OPTIMISING DOSES IN CETUXIMAB OR BEVACIZUMAB REGIMENS

4CPS-116

VEMURAFENIB-INDUCED STEVENS-JOHNSON SYNDROME IN A PATIENT WITH METASTATIC MELANOMA: A CASE REPORT

4CPS-115

RITUXIMAB IN THE TREATMENT OF PRIMARY GLOMERULONEPHRITIS

4CPS-114

DOSING OF PLATINUM AND TAXANES IN OBESE PATIENTS: A SYSTEMATIC REVIEW

4CPS-113

DRUG COST SAVING RESULTING FROM METASTATIC MELANOMA CLINICAL TRIALS

4CPS-112

ASSESSMENT OF AGGRESSIVE CARE IN ONCOLOGY PATIENTS AT THE END OF LIFE IN CLINICAL PRACTICE

4CPS-111

TREATMENT OF FOLLICULAR LYMPHOMA IN ROUTINE CLINICAL PRACTICE.

4CPS-110

SAFETY AND EFFECTIVENESS OF OBINUTUZUMAB IN CHRONIC LYMPHOCYTIC LEUKAEMIA: OUR EXPERIENCE

4CPS-109

POTENTIAL DRUG-DRUG INTERACTIONS INVOLVING TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA TREATED AT A UNIVERSITY HOSPITAL

4CPS-108

DABRAFENIB AND TRAMETINIB: COMBINATION THERAPY FOR METASTATIC MELANOMA

4CPS-107

EFFECTIVENESS AND SAFETY STUDY OF NIVOLUMAB IN THE SECOND LINE OF ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER

Pages